LEXX Lexaria Bioscience
- 3.2850
- -0.3050-8.50%
Lexaria Bioscience News
Maxim Group Maintains Lexaria Bioscience(LEXX.US) With Buy Rating, Maintains Target Price $12
Express News | HC Wainwright & Co. Reiterates Buy on Lexaria Bioscience, Maintains $10 Price Target
H.C. Wainwright Maintains Lexaria Bioscience(LEXX.US) With Buy Rating, Maintains Target Price $10
Buy Rating on Lexaria Bioscience Fueled by Promising DehydraTECH Advances in Diabetes Drug Development
Lexaria Bioscience Third Quarter 2024 Earnings: Misses Expectations
Express News | Lexaria Bioscience Corp - Dehydratech Appears to Be Working With Semaglutide Both With and Without Snac Technology
Express News | Lexaria Bioscience Corp - Dehydratech-Cbd Is Showing Strong Apparent Performance Relative to GLP-1
Express News | Lexaria Bioscience Corp - Dehydratech Appears to Work With a Second GLP-1 Drug - Liraglutide
Express News | Positive Interim Body Weight Results From Lexaria's Diabetes Animal Study
Lexaria Preparing For Strategic Growth, Expanding Its Management Team This Summer As It Prepares For The Greater Workload Of Multiple Projects And Initiatives; Appoints Nelson Cabatuan As Chief Strategic Financial Advisor, Resigning From His Current...
Express News | Lexaria Bioscience Corp - Is Also in Conceptual Design Stages of Additional R&D Projects Related to Additional GLP-1 Molecules of Interest
Express News | Lexaria Bioscience Corp - Nelson Is Resigning From His Current Role as CFO
Express News | Lexaria Bioscience Corp - Appointing Nelson Cabatuan as Our Consulting Chief Strategic Financial Advisor
Express News | Lexaria Bioscience Corp - Lexaria Will Be Expanding Its Management Team This Summer
Express News | Lexaria Bioscience Corp - Lexaria Preparing for Strategic Growth
Lexaria Preparing For Strategic Growth
Express News | Lexaria Bioscience Corp - Qtrly Shr Loss $0.13
10-Q: Q3 2024 Earnings Report
Lexaria Bioscience Initiated at Buy by HC Wainwright & Co.
Lexaria Bioscience Analyst Ratings
Analysis
Price Target
No Data
